Benzinga | Sep 7, 2021 06:14AM EDT

Morgan Stanley Downgrades Vertex Pharmaceuticals to Underweight, Announces $202 Price Target

Morgan Stanley analyst Matthew Harrison downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Equal-Weight to Underweight and announces $202 price target.